Systematic Review of Drug Delivery and Therapeutic Agents in Clinical Trials for the Treatment of Traumatic Brian Injuries
Description
Drug Delivery in patients diagnosed with a traumatic brain injury (TBI) is altered due to physiological changes such as the disrupted blood-brain barrier (BBB), which is difficult to permeate. Ensuring efficacy standards are met is challenging because therapeutic agents used for the treatment of TBIs may have different effects. While improving efficacy, it is also vital to reduce the risk of side effects and complications that may arise. When administering a drug to a TBI patient, advanced drug delivery methods are required such as convention-enhanced delivery (CED), nanoparticle delivery, and mitochondrial drug delivery. These advanced methods help to overcome the challenges systemic routes face, such as bypassing first pass metabolism, crossing the BBB, and entering straight into the brain tissue. After utilizing the advanced drug delivery methods and the drug has entered the brain tissue, then the drug can be observed to categorically distinguish the function and effectiveness for the treatment of TBIs. Here we report on advanced drug delivery methods and provide a systematic review of the therapeutic agents used in clinical trials for the treatment of TBIs. The database that was used to obtain information was PubMed, and original research as well as reviews were utilized. We have created a table from original research studies that organize the therapeutic drugs and lists their characteristics. Some of the promising technologies and therapies include mitochondrial drug delivery, nanoparticles, stem cell and non stem cell exosomes, cell penetrating peptides, and regulation of osmotic pumps. These therapies are essential to treatment because they account for the tedious nature of drug delivery in TBIs. By changing the mode of drug delivery by modifications and engineering particles that are specifically designed to reach the target site, therapeutic agents can accurately reach the desired area and begin providing relief to brain injured patients. TBIs are a difficult condition to treat and manage. With few long term TBI studies available, it is challenging to understand the brevity of this condition and what the implications of treatment are. However, new technologies make it possible for individuals to regain functionality in their brain.
Disciplines
Neurosciences | Other Medicine and Health Sciences | Pharmacy and Pharmaceutical Sciences
Keywords
Traumatic Brain Injury, Nanoparticles, Treatment, Stem-cell Derived Exosomes, Drug Carrier, Drug Delivery, Silk Fibroin
Document Type
Poster
Link to Published Version
https://acrobat.adobe.com/id/urn:aaid:sc:us:585f1bc0-83a5-4c3c-aeed-4d547eece17b
Recommended Citation
Lee, Stella and Dey, Surajit, "Systematic Review of Drug Delivery and Therapeutic Agents in Clinical Trials for the Treatment of Traumatic Brian Injuries" (2026). Annual Research Symposium. 3.
https://ecommons.roseman.edu/researchsymposium/2026/clinical/3
Systematic Review of Drug Delivery and Therapeutic Agents in Clinical Trials for the Treatment of Traumatic Brian Injuries
Drug Delivery in patients diagnosed with a traumatic brain injury (TBI) is altered due to physiological changes such as the disrupted blood-brain barrier (BBB), which is difficult to permeate. Ensuring efficacy standards are met is challenging because therapeutic agents used for the treatment of TBIs may have different effects. While improving efficacy, it is also vital to reduce the risk of side effects and complications that may arise. When administering a drug to a TBI patient, advanced drug delivery methods are required such as convention-enhanced delivery (CED), nanoparticle delivery, and mitochondrial drug delivery. These advanced methods help to overcome the challenges systemic routes face, such as bypassing first pass metabolism, crossing the BBB, and entering straight into the brain tissue. After utilizing the advanced drug delivery methods and the drug has entered the brain tissue, then the drug can be observed to categorically distinguish the function and effectiveness for the treatment of TBIs. Here we report on advanced drug delivery methods and provide a systematic review of the therapeutic agents used in clinical trials for the treatment of TBIs. The database that was used to obtain information was PubMed, and original research as well as reviews were utilized. We have created a table from original research studies that organize the therapeutic drugs and lists their characteristics. Some of the promising technologies and therapies include mitochondrial drug delivery, nanoparticles, stem cell and non stem cell exosomes, cell penetrating peptides, and regulation of osmotic pumps. These therapies are essential to treatment because they account for the tedious nature of drug delivery in TBIs. By changing the mode of drug delivery by modifications and engineering particles that are specifically designed to reach the target site, therapeutic agents can accurately reach the desired area and begin providing relief to brain injured patients. TBIs are a difficult condition to treat and manage. With few long term TBI studies available, it is challenging to understand the brevity of this condition and what the implications of treatment are. However, new technologies make it possible for individuals to regain functionality in their brain.